PMID- 35029038
OWN - NLM
STAT- MEDLINE
DCOM- 20220323
LR  - 20220323
IS  - 1759-7714 (Electronic)
IS  - 1759-7706 (Print)
IS  - 1759-7706 (Linking)
VI  - 13
IP  - 4
DP  - 2022 Feb
TI  - Apatinib as maintenance therapy following standard first-line chemotherapy in 
      extensive disease small cell lung cancer: A phase II single-arm trial.
PG  - 557-562
LID - 10.1111/1759-7714.14298 [doi]
AB  - BACKGROUND: There is a need for the development of therapies to delay cancer 
      progression and prolong survival after initial chemotherapy for the treatment of 
      small cell lung cancer (SCLC). Since apatinib has been found to exert promising 
      effects on cancer patients after standard first-line chemotherapy, this study 
      aimed to investigate apatinib as a maintenance treatment following first-line 
      chemotherapy in extensive disease (ED)-SCLC. METHODS: The primary endpoints were 
      overall survival (OS) and progression-free survival (PFS). The secondary 
      endpoints included toxicity and safety. Apatinib (250 mg/day) was administered 
      during the chemotherapy interval and as maintenance therapy after 4-6 cycles 
      until the patient's disease progressed, the patient died, or became intolerant to 
      the drug's toxicity. RESULTS: The patients who received apatinib maintenance 
      treatment had a median PFS of 3.7 months (95% CI: 1.3-6.2 months). The median OS 
      was 16.3 months (95% CI: 9.7-22.8 months). The objective response rate and 
      disease control rate were 50.0% and 66.7%, respectively. Two patients required 
      dose reduction due to adverse effects (AEs). The most common AEs included 
      hypertension (n = 4, 33.3%) and hand-foot-skin reaction (n = 2, 16.7%). One 
      patient developed diarrhea, while another patient developed hemoptysis. The most 
      serious AE was intestinal obstruction. CONCLUSIONS: Apatinib maintenance therapy 
      showed promising efficacy and safety to extend the OS/PFS of patients with 
      ED-SCLC, thus making it a potent therapeutic option in future clinical practice. 
      Given the small sample size of this study, further studies with large sample 
      sizes are needed to validate the findings of the present study.
CI  - (c) 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and 
      John Wiley & Sons Australia, Ltd.
FAU - Teng, Fei
AU  - Teng F
AUID- ORCID: 0000-0001-8563-4288
AD  - Department of Medical Oncology, National Cancer Center/National Clinical Research 
      Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, Beijing, China.
FAU - Xing, Puyuan
AU  - Xing P
AD  - Department of Medical Oncology, National Cancer Center/National Clinical Research 
      Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, Beijing, China.
FAU - Yang, Ke
AU  - Yang K
AD  - Department of Medical Oncology, Cancer Hospital of Huanxing ChaoYang District 
      Beijing, Beijing, China.
FAU - Gao, Lizhen
AU  - Gao L
AD  - Department of Medical Oncology, Cancer Hospital of Huanxing ChaoYang District 
      Beijing, Beijing, China.
FAU - Tian, Zhongqiu
AU  - Tian Z
AD  - Department of Medical Oncology, Cancer Hospital of Huanxing ChaoYang District 
      Beijing, Beijing, China.
FAU - Li, Junling
AU  - Li J
AUID- ORCID: 0000-0002-7361-325X
AD  - Department of Medical Oncology, National Cancer Center/National Clinical Research 
      Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking 
      Union Medical College, Beijing, China.
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
DEP - 20220114
PL  - Singapore
TA  - Thorac Cancer
JT  - Thoracic cancer
JID - 101531441
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Pyridines)
RN  - 5S371K6132 (apatinib)
SB  - IM
MH  - *Antineoplastic Agents/therapeutic use
MH  - Humans
MH  - *Lung Neoplasms
MH  - Pyridines
MH  - *Small Cell Lung Carcinoma/drug therapy
PMC - PMC8841707
COIS- All authors declare that they have no conflicts of interest that might be 
      relevant to the content of this manuscript. The abstract of this paper was 
      presented at the IASLC 2021 World Conference on Lung Cancer as a poster 
      presentation. The poster's abstract was published in "Poster Abstracts" in 
      Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2021.08.674.
EDAT- 2022/01/15 06:00
MHDA- 2022/03/24 06:00
PMCR- 2022/02/01
CRDT- 2022/01/14 06:25
PHST- 2021/12/13 00:00 [revised]
PHST- 2021/11/01 00:00 [received]
PHST- 2021/12/14 00:00 [accepted]
PHST- 2022/01/15 06:00 [pubmed]
PHST- 2022/03/24 06:00 [medline]
PHST- 2022/01/14 06:25 [entrez]
PHST- 2022/02/01 00:00 [pmc-release]
AID - TCA14298 [pii]
AID - 10.1111/1759-7714.14298 [doi]
PST - ppublish
SO  - Thorac Cancer. 2022 Feb;13(4):557-562. doi: 10.1111/1759-7714.14298. Epub 2022 
      Jan 14.